je.st
news
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab
2014-09-03 05:50:17| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology 2014 in Madrid, Spain, September 26 - 30. Data on pembrolizumab are ... (more)
Tags: data
present
types
studies
Category:Biotechnology and Pharmaceuticals